Tumor size and survival in breast cancer- A reappraisal

Nature Reviews Clinical Oncology

Volumn 7, Issue 6, 2010, Pages 348-353

  Foulkes, William D ^a   Reis Filho, Jorge S ^b   Narod, Steven A ^c  

^a MCGILL UNIVERSITY   (Canada)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER SCREENING; CANCER STEM CELL; CANCER SURVIVAL; DISEASE MARKER; DISTANT METASTASIS; GENE MUTATION; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; NONHUMAN; ONCOGENE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THERAPY DELAY; TUMOR GROWTH; TUMOR VOLUME; BREAST NEOPLASMS; FEMALE; MORTALITY; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS;

EID: 77953137221     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.39     Document Type: Review

References (54)

1. Sotiriou, C. & Piccart, M. J. Taking geneexpression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer 7, 545-553 (2007).
2. Weigelt, B., Baehner, F. L. & Reis-Filho, J. S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220, 263-280 (2010).
3. Mook, S. et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 10, 1070-1076 (2009).
4. Singletary, S. E. et al. Revision of the American Joint committee on cancer staging system for breast cancer. J. Clin. Oncol. 20, 3628-3636 (2002).
5. Fisher, B., Slack, N. H. & Bross, I. D. Cancer of the breast: size of neoplasm and prognosis. Cancer 24, 1071-1080 (1969).
6. Smart, C. R., Myers, M. H. & Gloeckler, L. A. Implications from seer data on breast cancer management. Cancer 41, 787-789 (1978).
7. Carter, C. L., Allen, C. & Henson, D. E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63, 181-187 (1989).
8. Olivotto, I. A. et al. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer 83, 948-955 (1998).
9. Sutcliffe, P. et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol. Assess. 13, 1-242 (2009).
10. Cheang, M. C. et al. Ki67 index, Her2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101, 736-750 (2009).
11. Norton, L. & Massague, J. Is cancer a disease of self-seeding? Nat. Med. 12, 875-878 (2006).
12. Norton, L. Gompertzian model of human breast cancer growth. Cancer Res. 48, 7067-7071 (1988).
13. Honrado, E., Benitez, J. & Palacios, J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod. Pathol. 18, 1305-1320 (2005).
14. Bernards, R. & Weinberg, R. A. A progression puzzle. Nature 418, 823 (2002).
15. Collett, K. et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol. Biomarkers Prev. 14, 1108-1112 (2005).
16. Komenaka, I. K. et al. The development of interval breast malignancies in patients with BrcA mutations. Cancer 100, 2079-2083 (2004).
17. Rakha, E. A., Reis-Filho, J. S. & Ellis, I. O. Basallike breast cancer: a critical review. J. Clin. Oncol. 26, 2568-2581 (2008).
18. Wirapati, P. et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10, r65 (2008).
19. Desmedt, C. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158-5165 (2008).
20. Van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
21. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
22. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429-4434 (2007).
23. Tischkowitz, M. et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7, 134 (2007).
24. Cheang, M. C. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14, 1368-1376 (2008).
25. Foulkes, W. D. et al. The prognostic implication of the basal-like (cyclin e high/p27 low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BrcA1-related breast cancer. Cancer Res. 64, 830-835 (2004).
26. Arnes, J. B. et al. Placental cadherin and the basal epithelial phenotype of BrcA1-related breast cancer. Clin. Cancer Res. 11, 4003-4011 (2005).
27. Foulkes, W. D., Grainge, M. J., Rakha, E. A., Green, A. R. & Ellis, I. O. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res. Treat. 117, 199-204 (2008).
28. Dent, R. et al. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer 115, 4917-4923 (2009).
29. Foulkes, W. D. et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BrcA1-related breast carcinoma. Cancer 98, 1569-1577 (2003).
30. Rennert, G. et al. Clinical outcomes of breast cancer in carriers of BrcA1 and BrcA2 mutations. N. Engl. J. Med. 357, 115-123 (2007). (Pubitemid 47057729)
31. Gonzalez-Angulo, A. M. et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J. Clin. Oncol. 27, 5700-5706 (2009).
32. Curigliano, G. et al. Clinical relevance of Her2 overexpression/ amplification in patients with small tumor size and node-negative breast cancer. J. Clin. Oncol. 27, 5693-5699 (2009).
33. Haupt, H. M., Rosen, P. P. & Kinne, D. W. Breast carcinoma presenting with axillary lymph node metastases. An analysis of specific histopathologic features. Am. J. Surg. Pathol. 9, 165-175 (1985).
34. Wicha, M. S., Liu, S. & Dontu, G. Cancer stem cells: an old idea-A paradigm shift. Cancer Res. 66, 1883-1890 (2006).
35. Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
36. Shackleton, M., Quintana, E., Fearon, E. R. & Morrison, S. J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829 (2009).
37. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
38. Honeth, G. et al. The cD44+/cD24- phenotype is enriched in basal-like tumors. Breast Cancer Res. 10, r53 (2008).
39. Wright, M. H. et al. Brca1 breast tumors contain distinct cD44+/cD24- and cD133+ cells with stem cell characteristics. Breast Cancer Res. 10, r10 (2008).
40. Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer cell stem content. Cell 140, 62-73 (2010).
41. Lim, E. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BrcA1 mutation carriers. Nat. Med. 15, 907-913 (2009).
42. Weigelt, B., peterse, J. L. & Van't Veer, L. J. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591-602 (2005).
43. Natrajan, R. et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, Her2 and luminal cancers. Breast Cancer Res. Treat. doi:10.1007/s10549-009-0501-3.
44. Holstege, H. et al. High incidence of proteintruncating Tp53 mutations in BrcA1-related breast cancer. Cancer Res. 69, 3625-3633 (2009).
45. Natrajan, R. et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin. Cancer Res. 15, 2711-2722 (2009).
46. Chin, K. et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529-541 (2006).
47. Adelaide, J. et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 67, 11565-11575 (2007).
48. Stephens, P. J. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005-1010 (2009).
49. Cicalese, A. et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138, 1083-1095 (2009).
50. Carey, L. A. et al. Race, breast cancer subtypes, and survival in the carolina Breast cancer study. JAMA 295, 2492-2502 (2006).
51. Tilanus-Linthorst, M. et al. A BrcA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int. J. Cancer 102, 91-95 (2002).
52. evans, A. J. et al. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. J. Med. Screen. 14, 210-214 (2007).
53. Robson, M. E. et al. A combined analysis of outcome following breast cancer: differences in survival based on BrcA1/BrcA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6, r8-r17 (2004).
54. Kriege, M. et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BrcA1 and BrcA2 mutation carriers. J. Clin. Oncol. 27, 3764-3771 (2009).